UC Riverside-led mouse study stresses MS treatment should be started early Author: Iqbal Pittalwala
Share This:
A team led by a biomedical scientist at the University of California, Riverside, reports a drug an estrogen receptor ligand called indazole chloride (IndCl) has the potential to improve vision in patients with multiple sclerosis, or MS.
The study, performed on mice induced with a model of MS and the first to investigate IndCl’s effect on the pathology and function of the complete afferent visual pathway, is published in Brain Pathology. The afferent visual pathway includes the eyes, optic nerve, and all brain structures responsible for receiving, transmitting, and processing visual information.